1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 30, 31/Jul/2025
  4. Article
Perspective Open Access
Like 0
Download

SDG 3: Tuberculosis

Abstract

Tuberculosis (TB) preventive treatment (TPT) is crucial for preventing infection with from progressing to TB disease, especially among people in high-risk groups. The expansion of novel TPT regimens for drug-susceptible TB is a notable advancement in TB care. However, managing contacts of drug-resistant TB patients remains a major challenge, particularly in Eastern Europe and Central Asia. In 2020, the World Health Organization (WHO) recommended TPT for high-risk household contacts of multidrug-resistant (MDR) or rifampicin-resistant (RR) TB patients; this was further reinforced in 2024 with a recommendation of a 6-month levofloxacin (6-Lfx) regimen. This Perspective discusses the early adoption of 6-Lfx for MDR/RR-TPT in the WHO European Region. In 2023, 38 of 53 WHO European Region countries reported on 6-Lfx use, with only eight confirming its use for MDR-TB contact persons. Accelerating the adoption of the 6-Lfx regimen and other evidence-backed TPT regimens is crucial for achieving TB elimination in the WHO European Region. Addressing challenges such as slow uptake of the recommendations, low awareness in affected communities and resource shortages are essential for success.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.30.2500210
2025-07-31
2025-08-04
/content/10.2807/1560-7917.ES.2025.30.30.2500210
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/30/eurosurv-30-30-3.html?itemId=/content/10.2807/1560-7917.ES.2025.30.30.2500210&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: WHO; 2020. Available from: https://iris.who.int/handle/10665/331170
  2. World Health Organization Regional Office for Europe (WHO/Europe). Tuberculosis action plan for the WHO European Region, 2023-2030. Copenhagen: WHO/Europe; 2023. Available from: https://iris.who.int/handle/10665/373409
  3. World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment, second edition. Geneva: WHO; 2024. Available from: https://iris.who.int/handle/10665/378536
  4. World Health Organization (WHO). The END TB strategy. Geneva: WHO; 2015. Available from: https://iris.who.int/handle/10665/331326
  5. World Health Organization (WHO). Towards tuberculosis elimination: an action framework for low-incidence countries. Geneva: WHO; 2014. Available from: https://iris.who.int/handle/10665/132231
  6. World Health Organization Regional Office for Europe (WHO/Europe). Tuberculosis elimination in the WHO European Region: review of key actions, with a special focus on tuberculosis infection management. Copenhagen: WHO/Europe; 2020. Available from: https://iris.who.int/handle/10665/336973
  7. European Centre for Disease Prevention and Control (ECDC) and WHO Regional Office for Europe. (WHO/Europe). Tuberculosis surveillance and monitoring in Europe 2025 – 2023 data. Copenhagen and Stockholm: WHO/Europe and ECDC; 2025. Available from: https://iris.who.int/handle/10665/380832
  8. Hesseling AC, Purchase SE, Martinson NA, Fairlie L, Schaaf HS, Brigden J, et al. Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis. N Engl J Med. 2024;391(24):2315-26.  https://doi.org/10.1056/NEJMoa2314318  PMID: 39693542 
  9. Fox GJ, Nhung NV, Cam Binh N, Hoa NB, Garden FL, Benedetti A, et al. Levofloxacin for the prevention of multidrug-resistant tuberculosis in Vietnam. N Engl J Med. 2024;391(24):2304-14.  https://doi.org/10.1056/NEJMoa2314325  PMID: 39693541 
  10. World Health Organization (WHO). Global Programme on Tuberculosis and Lung Health: Data. Geneva: WHO. [Accessed: 21 Mar 2025]. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/data
  11. Solovyeva AV, Volchenkov GV, Ponomarenko OI, Kuznezova TA, Somova TR, Belova EV, et al. Safety, efficacy, and feasibility of preventive treatment for drug-resistant tuberculosis with moxifloxacin or bedaquiline. medRxiv. 2025.03.09.25323266 .  https://doi.org/10.1101/2025.03.09.25323266 
  12. World Health Organization Regional Office for Europe (WHO/Europe). Gearing up towards ending TB in Europe: Regional workshop on prevention and systematic screening (PASS to EndTB). Copenhagen: WHO/Europe; 2023. Available from: https://www.who.int/europe/news-room/events/item/2023/10/30/default-calendar/gearing-up-towards-ending-tb-in-europe--regional-workshop-on-prevention-and-systematic-screening-(pass-to-endtb)
  13. World Health Organization (WHO). Screen TB. Optimizing strategies for tuberculosis screening. Geneva: WHO. [Accessed: 24 Jul 2025]. Available from: https://screentb.who.int/
  14. World Health Organization Regional Office for Europe (WHO/Europe). The European Prevention and Systematic Screening Initiative to End TB (PASS to End TB). Copenhagen: WHO/Europe. [Accessed: 21 Mar 2025]. Available from: https://www.who.int/europe/initiatives/the-european-prevention-and-systematic-screening-initiative-to-end-tb-pass-to-end-tb
  15. Dadu A, Yedilbayev A, Migliori GB, Ahmedov S, Falzon D, den Boon S, et al. PASS to End TB in Europe: Accelerated efforts on prevention and systematic screening to end tuberculosis in the WHO European Region by 2030. Int J Infect Dis. 2024;141S:106980.  https://doi.org/10.1016/j.ijid.2024.02.023  PMID: 38403111 
Early adopters of 6-month levofloxacin as rifampicin-resistant tuberculosis preventive treatment regimen in the WHO European Region, 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Irina+Felker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Felker Irina</a>, <a href="/search?value1=Alexandra+Solovyeva&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Solovyeva Alexandra</a>, <a href="/search?value1=Ana+Ciobanu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ciobanu Ana</a>, <a href="/search?value1=Araksya+Hovhannesyan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hovhannesyan Araksya</a>, <a href="/search?value1=Dennis+Falzon&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Falzon Dennis</a>, <a href="/search?value1=Andrei+Dadu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dadu Andrei</a></span>. Early adopters of 6-month levofloxacin as rifampicin-resistant tuberculosis preventive treatment regimen in the WHO European Region, 2023. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(30):pii=2500210. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.30.2500210" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.30.2500210</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 21 Mar 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 03 Jun 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.30.2500210
/content/10.2807/1560-7917.ES.2025.30.30.2500210
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error